keyword
https://read.qxmd.com/read/38749903/retifanlimab-in-advanced-penile-squamous-cell-carcinoma-the-phase-2-orpheus-study
#41
JOURNAL ARTICLE
Xavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, Pablo Maroto, Patrizia Giannatempo, Daniel Castellano, Miguel A Climent, Begoña P Valderrama, Alfonso Gómez de Liaño, Laura López-Montero, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo-Cordero, Andrea Necchi
BACKGROUND AND OBJECTIVE: Patients with advanced penile squamous cell carcinoma (PSCC) have poor outcomes and very limited therapeutic options are available. Most PSCC cases have high PD-L1 expression, which is associated with worse prognosis. Immunotherapy targeting PD-L1 could benefit patients with PSCC. Our aim was to evaluate the efficacy and safety of the anti-PD-1 antibody retifanlimab in patients with advanced/metastatic PSCC. METHODS: ORPHEUS was a single-arm, multicenter, phase 2 trial in 18 patients with advanced/metastatic PSCC, previously untreated with anti-PD-1/anti-PD-L1 agents...
May 14, 2024: European Urology Oncology
https://read.qxmd.com/read/38749879/oncological-and-functional-outcomes-of-penile-shaft-sparing-surgery-for-localised-penile-cancer-a-systematic-review
#42
REVIEW
Giuseppe Fallara, Giuseppe Basile, Adrian Poterek, Marco Tozzi, Karl H Pang, Omer Onur Çakir, Marco Bandini, Matteo Ferro, Gennaro Musi, Maria Satchi, Angelo Territo, Christian Fankhauser, Fabio Castiglione
CONTEXT: Penile shaft sparing (PSS) surgery for localised penile cancer (PeCa) aims to balance oncological and functional outcomes. OBJECTIVE: To summarise the published evidence on different PSS approaches. EVIDENCE ACQUISITION: We performed a systematic review adhering to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The systematic search was performed on PubMed, EMBASE, and Scopus databases up to February 14, 2023...
May 14, 2024: European Urology Focus
https://read.qxmd.com/read/38749854/risk-adjusted-screening-for-prostate-cancer-defining-the-low-risk-group-by-data-from-the-probase-trial
#43
JOURNAL ARTICLE
Agne Krilaviciute, Rudolf Kaaks, Petra Seibold, Maxime de Vrieze, Jale Lakes, Jan Philipp Radtke, Markus Kuczyk, Nina N Harke, Jürgen Debus, Christoph A Fink, Kathleen Herkommer, Jürgen E Gschwend, Valentin H Meissner, Axel Benner, Glen Kristiansen, Boris Hadaschik, Christian Arsov, Lars Schimmöller, Gerald Antoch, Frederik L Giesel, Marcus Makowski, Frank Wacker, Heinz-Peter Schlemmer, Nikolaus Becker, Peter Albers
BACKGROUND: Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr. OBJECTIVE: To identify men at age 45 yr with a low risk of PCa. DESIGN, SETTING, AND PARTICIPANTS: A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE)...
May 15, 2024: European Urology
https://read.qxmd.com/read/38749850/therapy-optimization-in-the-management-of-metastatic-hormone-sensitive-prostate-cancer-insights-from-the-arasens-study
#44
EDITORIAL
Axel S Merseburger, Simon Chowdhury, Amit Bahl
No abstract text is available yet for this article.
May 14, 2024: European Urology
https://read.qxmd.com/read/38749849/tp53-mutations-emerge-as-a-critical-biomarker-in-penile-cancer-superseding-human-papillomavirus-status
#45
EDITORIAL
Jad Chahoud, Xiaoqing Yu, Andrea Necchi, Philippe E Spiess
No abstract text is available yet for this article.
May 14, 2024: European Urology
https://read.qxmd.com/read/38749775/-surgical-and-pathological-consequences-of-preoperative-immunotherapy-in-onco-urology
#46
JOURNAL ARTICLE
Youssef Lyoubi, Sarah Bellal, Souhil Lebdai, Thibaut Culty, Cosmina Raluca Nedelcu Maniez, Faris Baowaidan, Merzouka Zidane Marrines, Pierre Bigot
INTRODUCTION: Patients treated with immunotherapy might need surgical procedures in addition to the medical treatment. The main indications are cytoreductive nephrectomy, cystectomy (as part of clinical trials) and metastasis removal in some oligometastatic patients. This study aims to assess the feasibility of surgery for patients treated by immunotherapy and describes the histological modifications found in the pathological analysis. MATERIAL AND METHODS: We conducted a retrospective, monocentric study...
May 14, 2024: Bulletin du Cancer
https://read.qxmd.com/read/38748865/comparison-of-systematic-and-combined-biopsy-for-the-detection-of-prostate-cancer
#47
JOURNAL ARTICLE
Jin-Lun Huang, Da Huang, Tsun-Tsun Chun, Chi Yao, Yong-Le Zhan, Xiao-Hao Ruan, Terence Chun-Ting Lai, Chiu-Fung Tsang, Karl-Ho Pang, Ada Tsui-Lin Ng, Dan-Feng Xu, Brian Sze-Ho Ho, Rong Na
Systematic prostate biopsy has limitations, such as overdiagnosis of clinically insignificant prostate cancer and underdiagnosis of clinically significant prostate cancer. Magnetic resonance imaging (MRI)-guided biopsy, a promising alternative, might improve diagnostic accuracy. To compare the cancer detection rates of systematic biopsy and combined biopsy (systematic biopsy plus MRI-targeted biopsy) in Asian men, we conducted a retrospective cohort study of men who underwent either systematic biopsy or combined biopsy at two medical centers (Queen Mary Hospital and Tung Wah Hospital, Hong Kong, China) from July 2015 to December 2022...
May 14, 2024: Asian Journal of Andrology
https://read.qxmd.com/read/38747982/the-impact-of-prostate-volume-estimation-on-the-risk-adapted-biopsy-decision-based-on-prostate-specific-antigen-density-and-magnetic-resonance-imaging-score
#48
JOURNAL ARTICLE
Arthur Baudewyns, Karsten Guenzel, Adam Halinski, Charles Dariane, Gina Delavar, Julien Anract, Nicolas Barry Delongchamps, Teddy Jabbour, Henri-Alexandre Bourgeno, Yolène Lefebvre, Mariaconsiglia Ferriero, Giuseppe Simone, Alexandre Fourcade, Georges Fournier, Marco Oderda, Paolo Gontero, Adrian Bernal-Gomez, Alessandro Mastrorosa, Jean-Baptiste Roche, Rawad Abou Zahr, Guillaume Ploussard, Gaelle Fiard, Katerina Rysankova, Alexandre Patrick Bui, Fayek Taha, Olivier Windisch, Daniel Benamran, Léonidas Vlahopoulos, Gregoire Assenmacher, Thierry Roumeguère, Alexandre Peltier, Romain Diamand
PURPOSE: Utility of prostate-specific antigen density (PSAd) for risk-stratification to avoid unnecessary biopsy remains unclear due to the lack of standardization of prostate volume estimation. We evaluated the impact of ellipsoidal formula using multiparametric magnetic resonance (MRI) and semi-automated segmentation using tridimensional ultrasound (3D-US) on prostate volume and PSAd estimations as well as the distribution of patients in a risk-adapted table of clinically significant prostate cancer (csPCa)...
May 15, 2024: World Journal of Urology
https://read.qxmd.com/read/38747153/end-stage-renal-disease-after-renal-cancer-surgery-risk-factors-and-overall-survival
#49
JOURNAL ARTICLE
John Åkerlund, Börje Ljungberg, Sven Lundstam, Ralph Peeker, Erik Holmberg, Marianne Månsson, Anna Grenabo Bergdahl
OBJECTIVE: Several risk factors for end-stage renal disease (ESRD), in patients undergoing surgical treatment for renal cell carcinoma (RCC), have been suggested by others. This study aimed to investigate such risk factors and disclose the effect of developing ESRD, postoperatively, on overall survival. The risk of developing ESRD after RCC diagnosis was also evaluated. MATERIAL AND METHODS: The data of 16,220 patients with RCC and 162,199 controls were extracted from the Renal Cell Cancer Database Sweden, with linkages across multiple national registers between 2005 and 2020...
May 15, 2024: Scandinavian Journal of Urology
https://read.qxmd.com/read/38747152/the-role-of-social-inequalities-in-the-epidemiology-of-urological-cancers-can-this-inform-cancer-screening
#50
JOURNAL ARTICLE
M G Cumberbatch
Health inequalities are systematic and potentially remediable differences in health across populations. Understanding the origins of these discrepancies, the healthcare consequences and the manifestations of related diseases can help improve the outcomes of underserved communities. Here I discuss how social factors may be used to help identify particular at-risk populations with regards to urological malignancies, and how these can be potentially used as biomarkers that inform cancer screening targets.
May 15, 2024: Annals of the Royal College of Surgeons of England
https://read.qxmd.com/read/38746673/the-clinical-effect-of-gratitude-extension-construction-theory-nursing-program-on-bladder-cancer-patients-with-fear-of-cancer-recurrence
#51
JOURNAL ARTICLE
Liping Qian, Yin Zhang, Hui Chen, Yuan Pang, Chenchen Wang, Liangmei Wang, Xiaoqing Zhang
OBJECTIVE: To explore the clinical effect of bladder cancer patients with Fear of Cancer Recurrence (FCR) after applying the gratitude extension construction theory nursing program. METHODS: 168 patients with bladder cancer hospitalized in the Department of Urology from December 2021 to June 2023 in a hospital are study subjects. The experimental subjects are uniformly designed as an experimental group and a control group, with 52 participants in each group. The former receives routine nursing care, while the later receives nursing interventions based on gratitude extension construction theory...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38745554/case-of-the-month-from-the-department-of-medical-oncology-peter-maccallum-cancer-centre-university-of-melbourne-australia-recurrent-metastatic-spermatocytic-tumour-successfully-treated-with-salvage-systemic-chemotherapy
#52
https://read.qxmd.com/read/38744934/accuracy-readability-and-understandability-of-large-language-models-for-prostate-cancer-information-to-the-public
#53
JOURNAL ARTICLE
Jacob S Hershenhouse, Daniel Mokhtar, Michael B Eppler, Severin Rodler, Lorenzo Storino Ramacciotti, Conner Ganjavi, Brian Hom, Ryan J Davis, John Tran, Giorgio Ivan Russo, Andrea Cocci, Andre Abreu, Inderbir Gill, Mihir Desai, Giovanni E Cacciamani
BACKGROUND: Generative Pretrained Model (GPT) chatbots have gained popularity since the public release of ChatGPT. Studies have evaluated the ability of different GPT models to provide information about medical conditions. To date, no study has assessed the quality of ChatGPT outputs to prostate cancer related questions from both the physician and public perspective while optimizing outputs for patient consumption. METHODS: Nine prostate cancer-related questions, identified through Google Trends (Global), were categorized into diagnosis, treatment, and postoperative follow-up...
May 14, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38744634/re-incidence-and-survival-of-secondary-malignancies-after-external-beam-radiotherapy-for-prostate-cancer-in-the-seer-database
#54
JOURNAL ARTICLE
Joseph L Chin
No abstract text is available yet for this article.
May 13, 2024: European Urology
https://read.qxmd.com/read/38744633/re-enfortumab-vedotin-and-pembrolizumab-in-untreated-advanced-urothelial-cancer
#55
JOURNAL ARTICLE
Martina Catalano, Matteo Santoni, Giandomenico Roviello
No abstract text is available yet for this article.
May 13, 2024: European Urology
https://read.qxmd.com/read/38744632/the-role-of-microsatellite-instability-dna-mismatch-repair-deficiency-and-tumor-mutational-burden-as-biomarkers-in-predicting-response-to-immunotherapy-in-castration-resistant-prostate-cancer
#56
EDITORIAL
Niklas Klümper, Viktor Grünwald, Arndt Hartmann, Michael Hölzel, Markus Eckstein
Large trials of immune checkpoint inhibitors (ICIs) in castration-resistant prostate cancer (CRPC) have mostly failed. Biomarker-selected CRPC patients, especially those with high microsatellite instability (MSI-H), mismatch repair deficiency (dMMR), or elevated tumor mutational burden (TMB), may benefit from single-agent ICIs. Despite their rarity in CRPC (∼2-5%), identification of MSI-H, dMMR, or TMB-H could improve patient selection for immunotherapy.
May 13, 2024: European Urology
https://read.qxmd.com/read/38744587/influential-factors-impacting-treatment-decision-making-and-decision-regret-in-patients-with-localized-or-locally-advanced-prostate-cancer-a-systematic-literature-review
#57
REVIEW
Benjamin A Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D Mundle, Sharon A McCarthy, Sabine D Brookman-May, Francesco De Solda, Ruhee Jain, Wellam Yu Ko, Guillaume Ploussard, Boris Hadaschik
CONTEXT: Treatment decision-making (TDM) for patients with localized (LPC) or locally advanced (LAPC) prostate cancer is complex, and post-treatment decision regret (DR) is common. The factors driving TDM or predicting DR remain understudied. OBJECTIVE: Two systematic literature reviews were conducted to explore the factors associated with TDM and DR. EVIDENCE ACQUISITION: Three online databases, select congress proceedings, and gray literature were searched (September 2022)...
May 13, 2024: European Urology Oncology
https://read.qxmd.com/read/38743486/l-2-hydroxyglutarate-remodeling-of-the-epigenome-and-epitranscriptome-creates-a-metabolic-vulnerability-in-kidney-cancer-models
#58
JOURNAL ARTICLE
Anirban Kundu, Garrett J Brinkley, Hyeyoung Nam, Suman Karki, Richard Kirkman, Madhuparna Pandit, EunHee Shim, Hayley Widden, Juan Liu, Yasaman Heidarian, Nader H Mahmoudzadeh, Alexander J Fitt, Devin Absher, Han-Fei Ding, David K Crossman, William J Placzek, Jason W Locasale, Dinesh Rakheja, Jonathan E McConathy, Rekha Ramachandran, Sejong Bae, Jason M Tennessen, Sunil Sudarshan
Tumor cells are known to undergo considerable metabolic reprogramming to meet their unique demands and drive tumor growth. At the same time, this reprogramming may come at a cost with resultant metabolic vulnerabilities. The small molecule L-2-hdroxyglutarate (L-2HG) is elevated in the most common histology of renal cancer. Similar to other oncometabolites, L-2HG has the potential to profoundly impact gene expression. Here, we demonstrate that L-2HG remodels amino acid metabolism in renal cancer cells through the combined effects on histone methylation and RNA N6-methyladenosine (m6A)...
May 14, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38743260/endoscopic-intervention-versus-radical-nephroureterectomy-for-the-management-of-localized-upper-urinary-tract-urothelial-carcinoma-a-systematic-review-and-meta-analysis-of-comparative-studies
#59
REVIEW
Carlo Giulioni, Carlo Brocca, Pietro Tramanzoli, Silvia Stramucci, Matteo Mantovan, Leonard Perpepaj, Andrea Cicconofri, Vineet Gauhar, Axel Stuart Merseburger, Andrea Benedetto Galosi, Daniele Castellani
OBJECTIVE: Localized Upper Urinary Tract Urothelial Carcinoma (UTUC) is an uncommon cancer typically detected at an advanced stage. Currently, radical nephroureterectomy (RNU) with bladder cuff excision is the standard treatment for high-risk UTUC. This meta-analysis aims to evaluate the 5-year overall and cancer-specific survival and bladder recurrence rates in studies comparing endoscopic kidney-sparing surgeries (E-KSS) with RNU in localized UTUC. EVIDENCE ACQUISITION: We performed a literature search on 20th April 2023 through PubMed, Web of Science, and Scopus...
May 14, 2024: World Journal of Urology
https://read.qxmd.com/read/38743063/the-2012-briganti-nomogram-not-only-predicts-lymph-node-involvement-but-also-disease-progression-in-surgically-treated-intermediate-risk-prostate-cancer-patients-with-psa-10-ng-ml-isup-grade-group-3-and-clinical-stage-up-to-ct2b
#60
JOURNAL ARTICLE
Antonio Benito Porcaro, Andrea Panunzio, Rossella Orlando, Francesca Montanaro, Alberto Baielli, Francesco Artoni, Sebastian Gallina, Alberto Bianchi, Giovanni Mazzucato, Emanuele Serafin, Giulia Marafioti Patuzzo, Alessandro Veccia, Riccardo Rizzetto, Matteo Brunelli, Filippo Migliorini, Riccardo Bertolo, Alessandro Tafuri, Maria Angela Cerruto, Alessandro Antonelli
PURPOSE: We assessed the prognostic impact of the 2012 Briganti nomogram on prostate cancer (PCa) progression in intermediate-risk (IR) patients presenting with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b treated with robot assisted radical prostatectomy eventually associated with extended pelvic lymph node dissection. MATERIALS AND METHODS: From January 2013 to December 2021, data of surgically treated IR PCa patients were retrospectively evaluated...
May 20, 2024: International Braz J Urol: Official Journal of the Brazilian Society of Urology
keyword
keyword
75195
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.